William Blair Has Bullish Estimate for Exelixis Q1 Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Research analysts at William Blair raised their Q1 2025 earnings estimates for shares of Exelixis in a research report issued on Tuesday, February 11th. William Blair analyst A. Hsieh now anticipates that the biotechnology company will post earnings of $0.40 per share for the quarter, up from their previous forecast of $0.39. The consensus estimate for Exelixis’ current full-year earnings is $1.74 per share.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 22.43% and a return on equity of 20.99%.

A number of other brokerages have also issued reports on EXEL. Stephens reissued an “equal weight” rating and set a $29.00 target price on shares of Exelixis in a research note on Wednesday. Piper Sandler increased their price objective on Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a report on Wednesday. Citigroup boosted their target price on Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday. Bank of America downgraded Exelixis from a “buy” rating to a “neutral” rating and raised their price target for the stock from $35.00 to $39.00 in a research note on Tuesday, December 17th. Finally, Brookline Capital Management initiated coverage on Exelixis in a report on Monday, December 23rd. They set a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.24.

Exelixis Stock Performance

EXEL stock opened at $34.49 on Friday. The stock has a market cap of $9.85 billion, a P/E ratio of 22.11, a P/E/G ratio of 0.63 and a beta of 0.53. The firm has a 50 day simple moving average of $34.21 and a 200 day simple moving average of $30.75. Exelixis has a 52 week low of $20.14 and a 52 week high of $37.59.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. CWM LLC grew its position in Exelixis by 73.3% during the third quarter. CWM LLC now owns 34,643 shares of the biotechnology company’s stock worth $899,000 after buying an additional 14,655 shares in the last quarter. V Square Quantitative Management LLC bought a new stake in shares of Exelixis in the 3rd quarter worth approximately $30,000. Inspire Advisors LLC grew its holdings in shares of Exelixis by 24.9% during the 3rd quarter. Inspire Advisors LLC now owns 25,207 shares of the biotechnology company’s stock worth $654,000 after purchasing an additional 5,023 shares in the last quarter. Blue Trust Inc. increased its position in shares of Exelixis by 54.2% during the third quarter. Blue Trust Inc. now owns 6,094 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 2,141 shares during the period. Finally, Friedenthal Financial acquired a new position in shares of Exelixis in the third quarter valued at $744,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In other news, EVP Patrick J. Haley sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $35.27, for a total transaction of $352,700.00. Following the completion of the transaction, the executive vice president now directly owns 278,665 shares in the company, valued at $9,828,514.55. The trade was a 3.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the sale, the executive vice president now directly owns 486,059 shares of the company’s stock, valued at $17,823,783.53. This represents a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 111,588 shares of company stock worth $3,981,864 over the last ninety days. Company insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.